Skip to main content

Kris Mahadeo

Professor of Pediatrics
Pediatrics, Transplant and Cellular Therapy
Pediatric Transplant and Cellular Therapy, 2400 Pratt Street, Durham, NC 27705

Overview


As a committed life-long learner, I am awed by the continued advancements in the field of pediatric transplant and cellular therapy (PTCT).   Following completion of my PTCT fellowship training at Duke, I have developed a career dedicated to expanding indications for PTCT and improving associated outcomes.  I have a special interest in the mitigation of endotheliopathies and continue to lead global harmonization efforts related to management of toxicities of therapy.  As the Division Chief of PTCT at Duke, I am committed to the ensuring our patients receive state of the art care with access to innovative research protocols that change the field.   We are committed to training the next generation of physicians in our field with a commitment to global partnerships to improve care for patients across the world.

Current Appointments & Affiliations


Professor of Pediatrics · 2023 - Present Pediatrics, Transplant and Cellular Therapy, Pediatrics
Chief, Division of Pediatric Transplant & Cellular Therapy · 2023 - Present Pediatrics, Transplant and Cellular Therapy, Pediatrics
Member of the Duke Cancer Institute · 2023 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT).

Journal Article Bone Marrow Transplant · January 13, 2026 SOS/VOD is a life-threatening complication of hematopoietic stem cell transplantation, especially in children, with incidences reaching up to 15-20%. Despite efforts, SOS/VOD remains unpredictable with significant morbidity and mortality. High-risk criteri ... Full text Link to item Cite

Reduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507

Conference Blood · November 3, 2025 AbstractBackground: Allogeneic hematopoietic stem-cell transplantation has curative potential for sickle cell disease (SCD). Event-free sur ... Full text Cite
View All Publications

Education


St. George's University, School of Medicine (West Indies) · 2003 M.D.
Adelphi University · 1999 B.S.